Organization
Hansa Biopharma
11 clinical trials
Clinical trial
An Open-label, Single Arm, Multi-centre, Phase II Study Investigating Safety, Tolerability, Efficacy, Pharmacodynamics and Pharmacokinetics of Imlifidase in Patients With Guillain-Barré Syndrome, in Comparison With Matched Control PatientsStatus: Completed, Estimated PCD: 2024-02-27
Clinical trial
A Prospective, Post-authorisation Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation, Including a Non-comparative Concurrent Reference CohortStatus: Recruiting, Estimated PCD: 2028-12-31
Clinical trial
An Open-label, Controlled, Randomized Phase 3 Trial Evaluating 12-month Kidney Function in Highly Sensitized (cPRA ≥99.9%) Kidney Tx Patients With Positive XM Against a Deceased Donor, Comparing Desensitization Using Imlifidase With SoCStatus: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Controlled, Open-label PA Efficacy and Safety Study in Imlifidase Desensitised Kidney Tx Patients With Positive XM Against a Deceased Donor Prior to Imlifidase Treatment, Including Non-comparative Registry and Concurrent Reference CohortsStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 3 Open-label, Controlled, Randomised, Multi-centre Trial Comparing Imlifidase and Standard-of-care With Standard-of-care Alone in the Treatment of Severe Anti-GBM Antibody Disease (Goodpasture Disease)Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Prospective, Long-term Confirmatory Follow up Trial in Highly Sensitized Patients Treated With Imlifidase or Standard of Care in the ConfIdeS (20-HMedIdeS-17) TrialStatus: Recruiting, Estimated PCD: 2027-12-31
Clinical trial
A Randomized, Open-Label, Multi-Centre, Active Control, Efficacy and Safety Study of Imlifidase in Eliminating Donor Specific Anti-HLA Antibodies in the Treatment of Active Antibody-Mediated Rejection in Kidney Transplant PatientsStatus: Completed, Estimated PCD: 2022-05-28
Clinical trial
A Prospective Observational, Long Term Follow up Study of Patients Treated With Imlifidase Prior to Kidney TransplantationStatus: Completed, Estimated PCD: 2023-02-14
Clinical trial
A Prospective, Observational Long-term Follow-up Trial of Kidney Transplant Patients Treated With Imlifidase or Plasma Exchange After an Active/Chronic Active Antibody-Mediated Rejection EpisodeStatus: Terminated, Estimated PCD: 2023-03-30
Clinical trial
An Open Label, Phase II Study to Investigate DSA Rebound in Patients With a Positive Crossmatch, Made Transplantable With ImlifidaseStatus: Active (not recruiting), Estimated PCD: 2024-03-01
Clinical trial
A Single-arm, Multi-centre Trial to Evaluate Efficacy and Safety of Imlifidase in Highly Sensitised Children (1-17 Years) Receiving a Kidney Transplant With Positive Crossmatch Against a Living or Deceased Donor Converted to Negative After Imlifidase TreatmentStatus: Recruiting, Estimated PCD: 2024-09-30